Current Research - Cancer Treatment | Theranostics Australia

Current Research

Theranostics Australia is involved in several Hollywood Hospital ethics approved clinical trials in diagnostic and therapeutic cancer agents. Theranostics Australia is in part supported by the Theranostics Research Foundation whose aim is to foster research in molecular imaging and targeting therapies for people with Alzheimer’s disease, dementia or cancer.  Theranostics Australia will also aid its sister organisations, Diagnostic Nuclear Imaging and Oceanic Molecular Pty Ltd both based at Hollywood Hospital, to collect and analyse imaging data in order to identify trends which may lead to the prevention or control of those diseases.

Theranostics Australia are currently carrying out the following trials:

Lutetium-177 OPS-201 for Progressive Metastatic Neuroendocrine Tumours

The OPS-201 trial has now commenced in Perth. This IPSEN sponsored trial involves the use of Lutetium-177 OPS-201 (also known as Satareotide) for treatment of progressive metastatic neuroendocrine tumours (NETs). Theranostics Australia is one of several sites worldwide currently recruiting (together with Peter Mac in Melbourne, Royal Free in London and Memorial Sloan Kettering in New York).

This agent binds to both activated and unactivated somatostatin receptors which are upregulated on these tumours. There is far higher binding via this mechanism than standard octreotate.

The protocol involves 3 cycles 8 weeks apart of intravenous Lu-177 OPS-201. All patients will have baseline Ga-68 octreotate imaging performed.

The treatment is available for all NET patients with progressive metastatic disease including gastric and pancreatic NETs, pulmonary carcinoids, paraganglionomas and phaeochromacytomas.

Patients who have previously had Lu-177 octreotate are not eligible. Patients may have had any other treatment including chemotherapy, radiotherapy or SSTR analogues.

Costs of all tests, treatment and follow up is covered by Ipsen. The study is open to all patients – public or private.

If you would like further information on the trial or would like to refer a patient for screening assessment please contact us via email: or phone: +61 8 9091 1081.

If you are interested in collaborating or participating in any of these trials or have concepts and ideas for new trials, please contact us at